Geron (GERN) Q2 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Geron Corporation: Geron Announces Two Presentations at Upcoming European Hematology Association Annual Congress
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses related to imetelstat, the Company s first-in-class telomerase inhibitor, will be made at the European Hematology Association (EHA) Annual Congress meeting to be held virtually from June 9 17. The abstracts for the posters are available on the EHA website at www.ehaweb.org. Both posters will be published on the EHA Virtual Congress platform on June 11, 2021. We are pleased that the EHA accepted both of our abstracts which allows us to present what we believe to be imetelstat s compelling potential to become a leading treatment for lower risk MDS and MF patients, said Aleksandra Rizo, M.D., Ph.D., Geron s Chief Medical Officer. The new data and analyses from our Phase 2 IMbark and IMerge trials continue to h
Operator
Good day and thank you for standing by and welcome to the Q1 2021 Geron earnings conference call. [Operator instructions]. I would now like to hand the conference over to your speaker today, Olivia Bloom. Please go ahead.
Olivia Bloom
Executive Vice President, Finance, Chief Financial Officer, and Treasurer
Great. Thank you, Celine and good afternoon, everyone. Welcome to this conference call to discuss Geron s first-quarter 2021 financial results and recent company events. I am joined today by Dr.
John Scarlett, Geron s, chairman and chief executive officer; and Dr. Aleksandra Rizo, Geron s chief medical officer. After the market closed today, we announced our first-quarter 2021 financial results via press release, which is available on our website. In addition, an archive of this webcast will be available on our website for 30 days.
Posted on 112
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, today reported financial results for the first quarter ended March 31, 2021, as well as company highlights and upcoming events. As of March 31, 2021, the Company had $244.7 million in cash and marketable securities, which is expected to fund operations until the end of 2022.
“We have worked diligently over the past quarter to advance our two Phase 3 clinical trials with registrational intent, and we remain laser focused on improving outcomes for patients and delivering significant value to our shareholders,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer.
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the fourth-quarter 2020 Geron earnings conference call. [Operator instructions] I would now like to hand the conference over to Olivia Bloom, Geron s chief financial officer. Thank you. Please go ahead, ma am.
Olivia Bloom
Chief Financial Officer
Thank you, Erica, and good afternoon, everyone. Thank you for joining us for today s conference call. I m joined today by Dr. John Scarlett, Geron s chairman and chief executive officer; and Aleksandra Rizo, our chief medical officer.
After the market close today, we announced our fourth quarter and year-end 2020 financial results and operational highlights via press release, which is available on our website under geron.com/investors. In addition, a live webcast of this call is available on our website, and an archive will be available for 30 days. Before we begin, please note that this presentation and question-and-answer session will contain forward-looking s